RT Journal Article
T1 Transcatheter Aortic Valve Replacement in Pure Native Aortic Valve Regurgitation
A1 Yoon, Sung-Han
A1 Schmidt, Tobias
A1 Bleiziffer, Sabine
A1 Schofer, Niklas
A1 Fiorina, Claudia
A1 Munoz-Garcia, Antonio J.
A1 Yzeiraj, Ermela
A1 Amat-Santos, Ignacio J.
A1 Tchetche, Didier
A1 Jung, Christian
A1 Fujita, Buntaro
A1 Mangieri, Antonio
A1 Deutsch, Marcus-Andre
A1 Ubben, Timm
A1 Deuschl, Florian
A1 Kuwata, Shingo
A1 De Biase, Chiara
A1 Williams, Timothy
A1 Dhoble, Abhijeet
A1 Kim, Won-Keun
A1 Ferrari, Enrico
A1 Barbanti, Marco
A1 Vollema, E. Mara
A1 Miceli, Antonio
A1 Giannin, Cristina
A1 Attizzani, Guiherme F.
A1 Kong, William K. F.
A1 Gutierrez-Ibanes, Enrique
A1 Jimenez Diaz, Victor Alfonso
A1 Wijeysundera, Harindra C.
A1 Kaneko, Hidehiro
A1 Chakravarty, Tarun
A1 Makar, Moody
A1 Sievert, Horst
A1 Hengstenberg, Christian
A1 Prendergas, Bernard D.
A1 Vincent, Flavien
A1 Abdel-Wahab, Mohamed
A1 Nombela-Franco, Luis
A1 Silaschi, Miriam
A1 Tarantini, Giuseppe
A1 Butter, Christian
A1 Ensminger, Stephan M.
A1 Hildick-Smith, David
A1 Petronio, Anna Sonia
A1 Yin, Wei-Hsian
A1 De Marco, Federico
A1 Testa, Luca
A1 Van Mieghem, Nicolas M.
A1 Whisenant, Brian K.
A1 Kuck, Karl-Heinz
A1 Colombo, Antonio
A1 Kar, Saibal
A1 Moris, Cesar
A1 Delgado, Victoria
A1 Maisano, Francesco
A1 Nietlispach, Fabian
A1 Mack, Michael J.
A1 Schofer, Joachim
A1 Schaefer, Ulrich
A1 Bax, Jeroen J.
A1 Frerker, Christian
A1 Latib, Azeem
A1 Makkar, Raj R.
K1 aortic regurgitation
K1 transcatheter valve implantation
K1 High-risk patients
K1 Heart-valve
K1 Transapical implantation
K1 Stenosis
K1 Experience
K1 Outcomes
K1 Prosthesis
K1 Registry
K1 System
AB BACKGROUND Limited data exist about safety and efficacy of transcatheter aortic valve replacement (TAVR) in patients with pure native aortic regurgitation (AR).OBJECTIVES This study sought to compare the outcomes of TAVR with early-and new-generation devices in symptomatic patients with pure native AR.METHODS From the pure native AR TAVR multicenter registry, procedural and clinical outcomes were assessed according to VARC-2 criteria and compared between early-and new-generation devices.RESULTS A total of 331 patients with a mean STS score of 6.7 +/- 6.7 underwent TAVR. The early-and new-generation devices were used in 119 patients (36.0%) and 212 patients (64.0%), respectively. STS score tended to be lower in the new-generation device group (6.2 +/- 6.7 vs. 7.6 +/- 6.7; p = 0.08), but transfemoral access was more frequently used in the early-generation device group (87.4% vs. 60.8%; p = moderate (4.2% vs. 18.8%; p= moderate compared with those with post-procedural AR = moderate was independently associated with 1-year all-cause mortality (hazard ratio: 2.85; 95% confidence interval: 1.52 to 5.35; p = 0.001).CONCLUSIONS Compared with the early-generation devices, TAVR using the new-generation devices was associated with improved procedural outcomes in treating patients with pure native AR. In patients with pure native AR, significant post-procedural AR was independently associated with increased mortality. (C) 2017 by the American College of Cardiology Foundation.
PB Elsevier science inc
SN 0735-1097
YR 2017
FD 2017-12-05
LK https://hdl.handle.net/10668/26862
UL https://hdl.handle.net/10668/26862
LA en
DS RISalud
RD Apr 17, 2025